Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by equities researchers at Stifel Nicolaus from ...

Barclays lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps an Overweight rating on the shares.Maximize Your ...

Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The ...

Full Year 2024 Results Key Financial Results Revenue: US$610.8m (down 1.3% from FY ...

As of 2023 year-end, the firm had $1.2 billion of debt, $1.6 billion of cash and cash equivalents, and $1.5 billion of deferred taxes that are largely related to its Sartorius investment. We forecast ...

Using a series of more than 1,000 X-ray snapshots of the shapeshifting of enzymes in action, researchers at Stanford ...

Learn how to invest in stocks, including how to select a brokerage account and research stock market investments. Many, or all, of the products featured on this page are from our advertising ...

A team of Chinese scientists has used targeted gene editing to develop rice that produces coenzyme Q10 (CoQ10), a vital ...

Researchers have created a novel imaging-technology combination that can capture gene activity in individual bacteria in ...

CFO Beth Jantzen reported total revenues of $1.2 million for Q1 2025, a year-over-year increase driven by higher product revenue from DNA Tagging and increased isotopic testing services. Operating ...

The provision will enable whole genome sequencing for neonatal and paediatric patients in intensive care units within 48 ...